Literature DB >> 8434497

The Bethesda System. Impact on reporting cervicovaginal specimens and reproducibility of criteria for assessing endocervical sampling.

M E Sherman1, M Weinstein, M Sughayer, J O Cappellari, J E Orr, Y S Erozan, M H Schiffman, R J Kurman.   

Abstract

This study examined the impact of applying the Bethesda System guidelines for specimen adequacy on cytopathologic diagnosis at the Johns Hopkins Hospital laboratory of cytopathology during a one-year period. Application of the Bethesda guidelines resulted in a 1.3% unsatisfactory rate. In addition, 3.8% of specimens were satisfactory but contained an inadequate endocervical component (IEC). Smears obtained after a cone biopsy or an initial IEC smear were IEC in 16.5% and 18.7% of cases, respectively. The IEC rate following an initial smear lacking an endocervical component was 11.8% in repeat specimens obtained with an endocervical brush as compared to 29.4% in those obtained with a spatula alone. The reproducibility of the Bethesda criteria for assessing endocervical sampling was evaluated by comparing the level of agreement between three independent reviewers examining 40 test cases. Three-way agreement was achieved in 75% of cases. Two-way agreement ranged from 80.0% to 87.5%. We conclude that implementation of the Bethesda System guidelines for assessing specimen adequacy should produce a minimal impact on cytopathologic reporting and gynecologic practice. Repeat specimens lacking an endocervical component may be encountered relatively frequently in certain subsets of patients.

Entities:  

Mesh:

Year:  1993        PMID: 8434497

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  2 in total

1.  [Use of the endocervical brush for taking a cervical smear].

Authors:  R Moreno Mira; J Cartanya Benet; C Serra Más; V Bonet Serra
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

2.  Current classification systems and standardized terminology in cytopathology.

Authors:  Tibor Mezei
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.